The Serum Institute of India (SII), the world’s biggest Covid-19 vaccine maker, is hopeful of launching Covovax – developed in partnership with American vaccine developer Novavax – by September this year, its CEO Adar Poonawalla said om the 27th of March.
“Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021,” Adar Poonawalla tweeted this afternoon.
Adar Poonawalla shared the development on his Twitter handle.
Adar Poonawalla shared the development on his Twitter handle.
The SII’s clinical trial for Covovax vaccine begins
Pune-based SII’s phase 2 and 3 bridging study of 1,600 participants for the Covovax vaccine has started at one of the trial sites in Pune, with at least one more site expected to begin screening as early as Tuesday.
“The trials have started at a hospital in Pune on Thursday. More will start enrolling soon.
Subscribe to our email newsletter to get the latest posts delivered right to your email.
Comments